HugoScore hugoscore.org

Ambient scribe

Nabla

Nabla is an AI clinical assistant for ambient documentation, EHR-integrated note generation, multilingual support, and clinician workflow relief. Its public materials are comparatively strong on consent examples, no audio storage by default, no AI training on clinical notes, and configurable retention, but patient notice, refusal, transcript access, and correction rights remain deployment-specific.

Public-source research has been drafted; final human publication review and change-log detail are still required.

40 /100 toward patient-directed
Agency posture Mixed
The question we ask Who does Nabla serve in this deployment?
Control Institutional or clinician-mediated use with patient impact
Agency read May help care, but must be tested for visibility, consent, correction, and institutional priority drift.
Vendor
Nabla Technologies
Who it serves
Institutional, clinician-mediated
Primary User
Clinicians and health systems
Control Model
Vendor and health system controlled
Patient Impact
Visit recording, note generation, EHR documentation, coding/order workflow, and future chart context
Profile Status
Draft profile
Last Reviewed
Jun 8, 2026
Review Confidence
Medium draft

Summary judgment · 40% toward patient-directed

Mixed

Nabla is institution-led and clinician-mediated, but public consent language, no-audio-by-default claims, and no-training-on-clinical-notes claims make patient-facing governance more inspectable.

Patient agency

How this tool changes agency

Expands agency when

Nabla may improve clinician attention and note completeness, but it is not a patient-controlled advocacy or navigation tool.

Limits agency when

Consent is described, but opt-out/refusal workflow, documentation, and alternatives remain deployment-specific.

Patient-facing signals

Who does this AI serve?

Institutional / clinician-mediated

Nabla is sold to clinicians and healthcare organizations for documentation and workflow support.

Can patients tell AI is involved?

Partial to yes

Nabla publishes consent language, but actual notice depends on clinician and health-system implementation.

Can patients meaningfully choose?

Partial

Consent is described, but opt-out/refusal workflow, documentation, and alternatives remain deployment-specific.

Can patients correct or challenge what the AI produces?

Partial

Clinician review is central, but patient transcript/audio access and AI-specific correction routes are not clearly established.

Does it help patients understand or act?

Indirectly

Nabla may improve clinician attention and note completeness, but it is not a patient-controlled advocacy or navigation tool.

Text findings

Who is left out or burdened?

Evidence incomplete

Nabla claims broad language/specialty support and FQHC deployment, but independent evidence by language, accent, disability, specialty, interpreter use, and safety-net context remains limited.

What happens to patient data?

Stronger public governance claims, still deployment-specific

Nabla says audio is not stored by default, notes are not used for AI training, and note retention is configurable. Health-system agreements and local settings still matter.

Are the clinical boundaries clear?

Mostly clear

The product is clinician-assistive and requires clinician review. Order, coding, and workflow features raise downstream safety questions.

Who defined what good looks like?

Mostly clinician, vendor, and health-system-defined

Published evidence includes patient experience but emphasizes clinician burden, documentation time, and adoption. Patient agency measures are not yet central.

Review method

Deep public-source review of official product pages, trust/security pages, consent guidance, privacy policy, customer/public evidence, and published ambient-scribe research; no vendor interview or hands-on deployment testing.

Draft profile · Medium draft